As of September 30, 2026, Autonomix Medical, Inc. carries a market capitalization of 7.51M, placing it among publicly traded companies globally. Its enterprise value stands at -185,437.46, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.51M |
| Enterprise Value | -185,437.46 |
Autonomix Medical, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of September 30, 2026, Autonomix Medical, Inc. has 1.96M shares outstanding.
| Shares Outstanding | 1.96M |
These figures are as of September 30, 2026.
| PB Ratio | 1.08 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | -0.22 |
| P/OCF Ratio | -0.22 |
As of September 30, 2026, Autonomix Medical, Inc. maintains a current ratio of 6.52, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.52 |
| Quick Ratio | 6.13 |
Over the twelve months ended September 30, 2026, Autonomix Medical, Inc. posted a negative return on equity (ROE) of -176.02, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -146.10, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 11.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -176.02 |
| Return on Assets (ROA) | -146.10 |
| Employee Count | 11.00 |
As of the close on November 16, 2026, Autonomix Medical, Inc.'s stock has declined approximately 92.79% over the past 52 weeks. The 50-day moving average sits at 2.99, while the 200-day moving average is 6.36.
| 52-Week Price Change | -92.79% |
| 50-Day Moving Average | 2.99 |
| 200-Day Moving Average | 6.36 |
Over the twelve months ended September 30, 2026, Autonomix Medical, Inc. generated - - in revenue and converted that into -11.78M in net income, yielding earnings per share of -17.07. EBITDA reached -12.01M, while operating income came in at -12.03M.
| Operating Income | -12.03M |
| Pretax Income | -11.78M |
| Net Income | -11.78M |
| EBITDA | -12.01M |
| EBIT | -12.03M |
| Earnings Per Share (EPS) | -17.07 |
These figures are as of September 30, 2026. Total book value stands at 6.94M, with working capital of 6.92M providing operational flexibility.
| Cash & Cash Equivalents | 7.69M |
| Net Debt | -7.69M |
| Equity (Book Value) | 6.94M |
| Book Value Per Share | 3.54 |
| Working Capital | 6.92M |
Autonomix Medical, Inc. produced -12.02M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -12.03M - equivalent to -17.43 per share.
| Operating Cash Flow | -12.02M |
| Capital Expenditures | -10,000.00 |
| Free Cash Flow | -12.03M |
| FCF Per Share | -17.43 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -455.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -163.19, meaning Autonomix Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -163.19 |
| FCF Yield | -455.01 |
Autonomix Medical, Inc.'s most recent stock split took place on June 24, 2026 with a 21:1 split ratio.
| Last Split Date | 6/24/2026 |
| Split Ratio | 21:1 |
As of September 30, 2026, Autonomix Medical, Inc. has an Altman Z-Score of -12.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.70 |